New CAR-T Makes Case for Aggressive Lymphomas

]]>(MedPage Today) -- ORLANDO--Three-fourths of patients with relapsed/refractory large B-cell lymphomas (LBCLs) responded to treatment with a new anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, according to the largest trial of its...